Clin2Atlas
AtlasOther conditionsDermatitis

Atopic dermatitis

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251990 — Fluticasone propionate approved (FDA)1994 — Tacrolimus anhydrous approved (FDA)2001 — Pimecrolimus approved (FDA)2016 — Crisaborole approved (FDA)2017 — Dupilumab approved (FDA)2021 — Abrocitinib approved (FDA)2021 — Tralokinumab approved (FDA)2023 — Lebrikizumab approved (FDA)
1990: Drug approval — Fluticasone propionate approved (FDA). 1994: Drug approval — Tacrolimus anhydrous approved (FDA). 2001: Drug approval — Pimecrolimus approved (FDA). 2016: Drug approval — Crisaborole approved (FDA). 2017: Drug approval — Dupilumab approved (FDA). 2021: Drug approval — Abrocitinib approved (FDA). 2021: Drug approval — Tralokinumab approved (FDA). 2023: Drug approval — Lebrikizumab approved (FDA)

What's being tested now

2004: 1 trials started2008: 1 trials started2010: 1 trials started2012: 1 trials started2014: 1 trials started2015: 2 trials started2017: 3 trials started2018: 1 trials started2019: 11 trials started2020: 6 trials started2021: 10 trials started2022: 12 trials started2023: 37 trials started2024: 46 trials started2025: 76 trials started2026: 83 trials started20102020202683

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 252 active Atopic Dermatitis trials on Clin2 →

Related

Contact dermatitisSeborrhoeic dermatitis

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.